Clickable Table

< back to the main pricing table
Generic Name Brand Name Strength Dosing 90 Day Cost Coverage Comments Category 1 Category 2
Regular insulin Novolin Toronto/Humulin R 100 U/ml As dir $70 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Repaglinide Gluconorm 1 mg TID $40 BC / NIHB - Covered Hypoglycemic Agents Meglitinides
Canagliflozin Invokana 100 mg QD $295 BC / NIHB - SA Hypoglycemic Agents Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Dapagliflozin Propanediol Monohydrate Forxiga 10 mg QD $80 BC / NIHB - Covered Hypoglycemic Agents Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Empagliflozin Jardiance 10 mg QD $290 BC - SA / NIHB - Covered Hypoglycemic Agents Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Gliclazide Diamicron 80 mg BID $35 BC / NIHB - Covered Hypoglycemic Agents Sulfonylureas
Gliclazide MR Diamicron MR 30 mg MR 2 QD $35 BC / NIHB - Covered Hypoglycemic Agents Sulfonylureas
Glyburide Diabeta 5 mg BID $25 BC / NIHB - Covered Hypoglycemic Agents Sulfonylureas
Metformin Glucophage 500 mg 2 BID $25 BC / NIHB - Covered Hypoglycemic Agents Biguanides
Metformin SR Glumetza SR 1000 mg 2 QD $260 BC - NC / NIHB - SA Hypoglycemic Agents Biguanides
Linagliptin Trajenta 5 mg QD $280 BC - SA / NIHB - Covered Hypoglycemic Agents Dipeptidylpeptidase-4 Inhibitors (DPP-4)
Saxagliptin Onglyza 5 mg QD $335 BC - SA / NIHB - Covered Hypoglycemic Agents Dipeptidylpeptidase-4 Inhibitors (DPP-4)
Sitagliptin Januvia 100 mg QD $335 BC / NIHB - SA Hypoglycemic Agents Dipeptidylpeptidase-4 Inhibitors (DPP-4)
Lixisenatide Adlyxine 0.02 mg SQ QD $390 BC - SA / NIHB - Covered Hypoglycemic Agents Glucagon-like Peptide 1 Agonist (GLP-1)
Semaglutide Ozempic 0.5 mg SQ Once weekly $720 BC / NIHB - SA Hypoglycemic Agents Glucagon-like Peptide 1 Agonist (GLP-1)
Liraglutide Victoza 1.2 mg SQ QD $730 BC / NIHB - NC Hypoglycemic Agents Glucagon-like Peptide 1 Agonist (GLP-1)
Liraglutide Victoza 1.8 mg SQ QD $1090 BC / NIHB - NC Hypoglycemic Agents Glucagon-like Peptide 1 Agonist (GLP-1)
Basal insulin (Degludec) Tresiba 100 U/ml As dir $135 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Basal insulin (Detemir) Levemir 100 U/ml As dir $140 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Basal insulin (Glargine) Lantus 100 U/ml As dir $120 BC - NC / NIHB - SA

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Basal insulin (Glargine) Toujeo 300 U/ml As dir $115 BC - NC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Basal insulin biosimilar (Glargine) Basaglar 100 U/ml As dir $100 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Long-acting insulin Novolin NPH/Humulin N 100 U/ml As dir $70 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Rapid-acting insulin Humalog 100 U/ml As dir $95 BC - NC / NIHB - SA

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Rapid-acting insulin Novorapid 100 U/ml As dir $85 BC - NC / NIHB - SA

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Rapid-acting insulin biosimilars Admelog 100 U/ml As dir $65 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Rapid-acting insulin biosimilars Trurapi 100 U/ml As dir $65 BC / NIHB - Covered

Prices may vary between pharmacies, relative differences likely consistent. Max allowable price for 1500 Units of penfill insulin. Lantus, Novorapid, and Humalog part of Blue Cross biosimilar initiative so only biosimilar alternatives are covered (Basaglar, Trurapi, and Admelog, respectively).

Hypoglycemic Agents Insulin
Legend:
BC = Alberta Blue Cross, NIHB = Non-Insured Health Benefits for First Nations and Inuit, NC = Not covered, SA = special authorization, SR = sustained release, OTC = over the counter, SQ = subcutaneous injection, SS=Social Services